指南与共识泌尿生殖技术与安全CTMRPET

前列腺癌分子影像与诊疗一体化共识

Consensus on molecular imaging and theranostics in prostate cancer.
指南 / 共识 · Lancet Oncol · 2018-01-01

欧洲核医学协会Focus 1会议召集多学科国际专家,结合系统文献综述与改良Delphi流程,就前列腺癌影像与放射性药物治疗形成共识。共识指出双膦酸盐骨扫描与增强CT很少被推荐,MRI与靶向前列腺癌PET常被建议但影响实践的具体情境尚未确立,镓-68或氟-18 PSMA PET获得认可,镭-223因生存获益已基本取代其他骨靶向放射性药物。

要点

  • 双膦酸盐骨扫描与增强CT在多数患者中很少被临床指南推荐。
  • MRI(全身或多参数)与靶向前列腺癌PET常被建议,但影响实践的具体情境尚未确立。
  • 镓-68或氟-18 PSMA PET获得认可,氟-18氟化钠PET-CT骨扫描未获广泛提倡。

核心结论

  • MRI与PET-CT的进步提高了影像准确性,但这些新方法对临床结局的影响仍待确立。
  • 双膦酸盐骨扫描与增强CT被提及但很少被临床指南推荐用于多数患者。
  • MRI(全身或多参数)与靶向前列腺癌PET常被建议,但影响实践的具体情境尚未确立。
  • 镓-68或氟-18 PSMA获得认可,而氟-18氟化钠PET-CT骨扫描未获广泛提倡。
  • 骨靶向放射性药物(铼-186、钐-153或锶-89)的姑息治疗已基本被镭-223及其他有生存获益证据的系统治疗取代。

研究设计与样本

  • 欧洲核医学协会Focus 1会议召集肿瘤内科、泌尿外科、放射肿瘤、放射与核医学专家形成共识。
  • 共识基于系统文献综述与改良Delphi流程。

临床应用与阅片要点

  • 影像医师与临床医师加强沟通、临床试验设计增加多学科投入,对推动影像洞察进入临床决策至关重要。

局限性

  • MRI与PET-CT虽提高影像准确性,但这些新方法对临床结局的影响仍待确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fanti S, Minozzi S, Antoch G, et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 2018. PMID: 30507436. doi:10.1016/S1470-2045(18)30604-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。